Press release
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
— BRINSUPRI® (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch; Approximately $172.7 Million for
About this update from Insmed Incorporated
[{"type":"text","content":"— BRINSUPRI® (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch; Approximately $172.7 Million for Full-Year 2025——ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2025 with Unaudited Global Revenues of Approximately $433.8 Million——Full-Year 2026 Global ARIKAYCE Revenues Expected to be Between $450 Million and $470 Million——Topline Data from Phase 3 ENCORE Study of ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Disease Now Anticipated in March or April of 2026—— Topline Data from Phase 2b CEDAR Study of Brensocatib in Patients with HS Now Anticipated in the Second Quarter of 2026—— Phase 3 PALM-ILD Study of TPIP in PH-ILD Initiated in the Fourth Quarter of 2025; Additional Phase 3 Studies Planned for PAH, PPF, and IPF in 2026—BRIDGEWATER, N.J., Jan. 9, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today provided an update on the Company's commercial and clinical programs and its outlook for 2026. These updates will be discussed as part of the Company's presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, at 3:00 p.m. PT (6:00 p.m. ET).\"2025 was a landmark year for the patients we serve, our company, and our people, during which we demonstrated what's possible when breakthrough science meets steadfast execution. Our strong BRINSUPRI launch and encouraging TPIP readout in PAH reinforced both the clinical potential of our growing portfolio and the remarkable discipline of our teams,\" said Will Lewis, Chair and Chief Executive Officer of Insmed. \"As monumental as this past year was, the road ahead is poised to be even more exciting. With numerous upcoming clinical and commercial catalysts across our designated therapeutic areas — Respiratory, Immunology & Inflammation, and Neuro & Other Rare — we believe that the next 18 months could accelerate our trajectory even further and bring us closer to helping more patients living with serious diseases.\"Preliminary Full-Year 2025 Global Net Product Revenues (Unaudited)The following table summarizes Insmed's preliminary unaudited fina...